



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	96692	NUTRA-LIFE CO-Q-MAX 150MG
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Vitaco Health Australia Pty Ltd	
<b>Postal Address</b>	PO Box 399, NORTH RYDE BC, NSW, 1670 Australia	
<b>ARTG Start Date</b>	2/09/2003	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . NUTRA-LIFE CO-Q-MAX 150MG

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	13/05/2020
---------------------	-------------------------	-----------------------	------------

### Permitted Indications

- Antioxidant/Reduce free radicals formed in the body
- Helps reduce/decrease free radical damage to body cells
- Maintain/support energy production
- Maintain/support general health and wellbeing
- Maintain/support cardiovascular system health
- Maintain/support healthy cardiovascular system function
- Maintain/support immune system health
- Maintain/support healthy immune system function
- Helps prevent dietary (state vitamin/mineral/nutrient) deficiency

### Indication Requirements

- Product presentation must not imply or refer to serious cardiovascular conditions.
- Product presentation must not imply or refer to serious immunological diseases.
- If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.
- Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

### Standard Indications

No Standard Indications included on Record

### Specific Indications

No Specific Indications included on Record

### Warnings

Public Summary



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

Do not take while on warfarin therapy without medical advice.

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

**Additional Product information**

**Pack Size/Poison information**

**Pack Size**

**Poison Schedule**

**Components**

**1 . Formulation 1**

**Dosage Form** Capsule, soft

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

<b>d-alpha-tocopherol</b>	<b>33.56 mg</b>
<b>Evening Primrose Oil</b>	<b>200 mg</b>
<b>Linseed Oil</b>	<b>200 mg</b>
<b>natural fish oil</b>	<b>200 mg</b>
Equivalent: eicosapentaenoic acid	36 mg
Equivalent: docosahexaenoic acid	24 mg
<b>ubidecarenone</b>	<b>150 mg</b>

**Other Ingredients (Excipients)**

**Gelatin**

**glycerol**

**iron oxide red**

**iron oxide yellow**

**lecithin**

**purified water**

**Soya Oil**

**white beeswax**

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary